Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C.

CONCLUSION: VR at week 6, but not at week 4, is an efficient predictor of both SVR and non-SVR to TVR-based triple therapy. PMID: 26609346 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26609346?dopt=Abstract

Source: World Journal of Hepatology - November 28, 2015 Category: Gastroenterology Tags: World J Hepatol Source Type: research